[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.176.252. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
November 20, 2002

Sertraline for Treatment of Depression in Acute Coronary Syndromes

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior Editor

 

Not Available

JAMA. 2002;288(19):2403. doi:10.1001/jama.288.19.2403-JLT1120-1-2

To the Editor: Dr Glassman and colleagues1 found no statistically significant difference between sertraline and placebo for the trial's primary outcome, the number of patients showing a greater than 5% decrease in LVEF. However, no confidence intervals (CIs) are provided, and this prevents the reader from assessing the uncertainty involved in the results. The authors do report an absolute risk increase of 0.4%, for which I calculate a 95% CI of −4.4% to 5.3%. As a clinician, I would consider an absolute risk increase of 2% or more clinically important enough to consider, and this possibility is well within the CI.

First Page Preview View Large
First page PDF preview
First page PDF preview
×